Battelle Ventures, LP, has spun out Hepregen Corporation from the Massachusetts Institute of Technology.
Greenleaf Health LLC announced that Andrew C. von Eschenbach, MD, who recently stepped down as Commissioner of the Food and Drug Administration (FDA), has joined the firm as Senior Advisor.
Researchers from Boston University School of Medicine (BUSM) are encouraging prenatal vitamin manufacturers to use only potassium iodide and not other sources of iodine in their products.
Millipore Corporation announced that it has purchased the assets associated with Epitome Biosystems’ EpiTag technology.
Findings by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.
ICG Commerce has signed an agreement with Teva Pharmaceuticals to manage part of their indirect spend.
Trialytics announced an expansion of its core services to include increased clinical trial data resources, multiple protocols, and a comprehensive physician lead qualification program.
Almac Clinical Technologies announced that it has added 6,000 square feet of space at its Yardley, Pennsylvania USA headquarters.
PPD, Inc. announced it has entered into a strategic collaboration with Merck.
GE Healthcare introduced the illustra triplePrep, a kit for rapid, simultaneous isolation of genomic DNA, RNA, and total denatured protein from a single undivided sample.
MDRNA, Inc. announced that it has entered into an agreement with Roche.
Yale researchers have filled in a missing gap on the molecular road map of Alzheimer's disease.
Researchers at the Genomics Institute of the Novartis Research Foundation (GNF) have identified a set of compounds that can trigger the proliferation of insulin-producing cells in the pancreas, using sophisticated high-throughput screening techniques.
Elan Corp. PLC announced it will cut 230 jobs in Ireland and the United States, representing 14 percent of its work force, as part of its long-running struggle to return to profitability.
Researchers at the University of Cincinnati have discovered genetic variations that may prove to be key predictors of risk for colon cancer and indicators of the disease’s progression.